
Overton FDA Nomination Withdrawn: What It Means for Pharmacists
Key Takeaways
- Withdrawal of Heidi Overton’s nomination preserves FDA leadership instability, with confirmation dynamics shifting further as Democrats are poised to control the Senate in January.
- A March-timed FDA mifepristone safety review could reinstate restrictions via REMS and labeling, including potential reimplementation of in-person prescribing.
With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.
The White House withdrew the
Overton needed the votes of all 12 Republicans on the committee, and people familiar with the decision told The New York Times it became clear Tuesday night that she lacked them. Committee Chair Sen. Bill Cassidy (R-LA), a physician, disputed that, writing that he believed she "would have had the votes to pass out of committee and pass the full Senate." He said antiabortion senators had sought final assurances on "life issues" and that the administration withdrew Overton "rather than make such commitments."1,2
Mifepristone Decision Moves to Another Leader
The FDA is conducting a safety review of mifepristone, requested by President Donald Trump, that could reinstate restrictions, including an in-person prescribing requirement. The agency has promised findings by March. At her September hearing, Overton said the drug "is safe and effective as labeled today," however, Republicans viewed her answers on the review as vague, and she had previously called it "dangerous to women."1-3
As
Vaccine Policy Remains Unsettled
Cassidy had called Overton's role in a summer executive order to reduce the number of vaccines recommended for children "almost disqualifying." Overton also backed the administration's plan to split the measles, mumps, and rubella vaccine into 3 separate shots.1,4
No single-antigen measles, mumps, or rubella vaccines are currently available in the US or worldwide. Pharmacists should continue immunizing eligible patients according to the American Academy of Pediatrics schedule and applicable state guidance, Brigid Groves, PharmD, MS, of the American Pharmacists Association, previously told Pharmacy Times.3
An Extended Acting Period
Kyle Diamantas, JD, the FDA's deputy commissioner for food, has served as acting commissioner since Marty Makary, MD, MPH, resigned in May. Federal vacancy law limits acting commissioners to 210 days, but the withdrawal resets that clock. Semafor reported that Sen. Roger Marshall (R-KS), a physician who lost his reelection bid in the 2026 midterm elections, could be the next nominee; the White House has not named one.4
Democrats take control of the US Senate in January, and the odds of confirming a nominee after that could be slim. The user fees that fund FDA drug reviews must be reauthorized, a process that Democrats' midterm gains may complicate.1
"Our entire medical supply chain is dependent on adequate FDA staffing, from new approvals to safety, quality, and inspections to shortage management, so ensuring that the agency is staffed appropriately should be a fundamental objective of the new commissioner," Tom Kraus, JD, MHS, of the American Society of Health-System Pharmacists, told Pharmacy Times in August.3
REFERENCES
1. Jewett C. White House withdraws nomination of Heidi Overton to be F.D.A. commissioner. The New York Times. November 17, 2026. Accessed November 20, 2026. https://www.nytimes.com/2026/11/17/us/overton-fda-nomination-withdrawn.html?unlocked_article_code=1.R1E.qulL.o-Z5Co4J7pqk&smid=url-share
2. Perrone M. White House pulls FDA nominee Heidi Overton after wavering support from Senate Republicans. Associated Press. November 18, 2026. Accessed November 20, 2026. https://apnews.com/article/fda-overton-trump-senate-kennedy-cassidy-15d9c3978ed4f77657900cc2c327d375
3. Halpern L. What Heidi Overton's FDA nomination could mean for pharmacy. Pharmacy Times. August 27, 2026. Accessed November 20, 2026. https://www.pharmacytimes.com/view/what-heidi-overton-s-fda-nomination-could-mean-for-pharmacy
4. Gardner J. White House pulls nomination for FDA nominee Overton. BioPharma Dive. November 18, 2026. Accessed November 20, 2026. https://www.biopharmadive.com/news/white-house-withdraw-heidi-overton-fda-commissioner-nomination/874961/
Related to this article








